Principal Investigator – IRB7726: Clinical Protocol for Post Market Evaluation of Akonya Eliminator

Principal Investigator – IRB7726: Clinical Protocol for Post Market Evaluation of Akonya Eliminator.
Co-Investigator – IRB# 6052 Protocol DXV 303: A Phase 3, open-label, multicentre study of efficacy and safety of Visipaque (Iodixanol) in subjects with suspected peripheral arterial occlusive disease undergoing intravenous contrast-enhanced computed tomographic angiography.
Co-Investigator – IRB# 5938. Randomized, multi-center open label study of the safety (open-label) and efficacy(open-label & blinded reader) of Magnevist injection-enhanced magnetic resonance arteriography (MRA) at two dose levels and 2-dimensional-time-of-flight (2D-TOF) MRA in patients undergoing MRA of the infrarenal aorta and peripheral arteries with intra-arterial subtraction angiography (i.e. DSA) as standard of reference.